Chargement en cours...
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID‐19 pandemic
Tofacitinib is a Janus Kinase 3 inhibitor that is used in the treatment of alopecia areata. We recommended our alopecia areata patients to discontinue their tofacitinib treatment during the COVID‐19 pandemic for an average of 80 days. We aimed to evaluate the drug use and the SARS‐CoV‐2 infection st...
Enregistré dans:
| Publié dans: | Dermatol Ther |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley & Sons, Inc.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7883269/ https://ncbi.nlm.nih.gov/pubmed/33405372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.14746 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|